BCRX BioCryst Pharmaceuticals, Inc.

Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek. Anthropic’s Claude AI recently sold its positions in Ardelyx Inc. (NASDAQ: ARDX) and Aris Mining Corp. (NYSE: ARIS) and replaced them with Syndax Pharmaceuticals Inc. […]

Beneath the headline-driven sentiment of biotech investing lies the true engine of value creation: portfolio durability, capital efficiency, and sustainable revenue compounding. Founded on the promise of structure-based drug design, BioCryst Pharmaceuticals (NASDAQ:BCRX) has evolved from a speculative research shop into a commercial-stage rare disease specialist. The company’s core operational drivers now center on maximizing […]

BCRX is flashing a historically bullish signal

BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event. Gayer, who became CEO on Jan. 1, said

On August 28, 2026, CNBC reported that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), now consistently profitable on the strength of its hereditary angioedema drug “Orladeyo,” is looking to acquire more rare disease treatments, according to CEO Charlie Gayer. Gayer, who took the role in January, said the company expects to keep growing profits every year and does […]

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

BioCryst Pharmaceuticals (BCRX) has drawn fresh attention after recent trading left the share price at US$8.12, with the stock down over the past week and month but modestly higher year to date. Recent trading tells a mixed story for BioCryst Pharmaceuticals, with the share price falling 18.47% over the past week and 16.63% over the past month, yet still showing an 8.27% year to date share price return and a 5.45% one year total shareholder return. This suggests that short term momentum is...

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 0.3% and

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index shedding 0.2% and the

RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.

BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema tr

Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients.

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey’s proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding […]

Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

CEO Gayer told CNBC in an interview that the company is now profitable and plans to use that cash to invest in other rare-disease medicines.

The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

BioCryst Pharmaceuticals (BCRX) is back in focus after raising its full year 2026 revenue outlook, reporting detailed second quarter earnings, and highlighting progress across its hereditary angioedema and rare disease pipeline. See our latest analysis for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' recent guidance upgrade and second quarter earnings are arriving alongside a 7 day share price return of 16.76% and a year to date share price return of 41.20%. However, the 5 year total...

BioCryst Pharmaceuticals stock has put up a 53.0% gain over the past three years, yet the current valuation checks still lean on the inexpensive side for this kind of run. That mix raises the question of whether the recent share price is keeping up with what the broader indicators suggest about value. Over the past three years the share price return of 53.0% points to investors already recognising progress at BioCryst Pharmaceuticals, which can limit how much easy upside is left. Revenue...

ORLADEYO revenue hit $158.2M with 10% growth as pediatric launch exceeded expectations.

The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Investors need to pay close attention to BCRX stock based on the movements in the options market lately.

BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to lose by letting someone else snap it up first?

BioCryst Pharmaceuticals Inc (BCRX) reports 45% revenue growth, strong Orladeo performance, and a strategic shift toward external pipeline development.

Moby summary of BioCryst Pharmaceuticals, Inc.'s Q2 2026 earnings call

BioCryst raised its full-year 2026 total revenue outlook to $690 million to $715 million, up from its previous estimates of $635 million to $660 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE. President and CEO Charlie Ga

BioCryst (BCRX) delivered earnings and revenue surprises of +114.29% and +18.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.